[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100467335":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":33,"locations":42,"responsibleParty":59,"collaborators":62,"id":66,"slug":32,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":32,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":32,"enrollmentInfo":74,"targetDuration":32,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":32,"overallStatus":45,"whyStopped":32,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Seoul National University Bundang Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tgfenon","EXPERIMENTAL","Choline fenofibrate (135mg as fenofibric acid) 1 tablet once daily oral administration regardless of diet",[13],"Drug: Choline fenofibrate",{"label":15,"type":16,"description":17,"interventionNames":18},"Policosanol 10","ACTIVE_COMPARATOR","Policosanol 10mg 1 tablet once daily oral administration",[19],"Drug: Policosanol",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Choline fenofibrate","choline fenofibrate 178.8mg (135mg as fenofibric acid)",[9],[9],{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Policosanol","policosanol 10mg",[15],[15],null,[34,39],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Soo Lim","CONTACT","+82-31-787-7035","limsoo@snu.ac.kr",{"name":40,"role":36,"phone":32,"phoneExt":32,"email":41},"Minji Sohn","rainbowmjs@naver.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"SNUBH","RECRUITING","Seongnam-si","Gyeonggi-do","13620","South Korea",{"type":51,"coordinates":52},"Point",[53,54],127.13778,37.43861,{"lat":54,"lon":53},[57],{"name":35,"role":36,"phone":58,"phoneExt":32,"email":38},"01097662706",{"type":60,"investigatorFullName":35,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Professor",[63],{"name":64,"class":65},"Daewon Pharmaceutical Co., Ltd.","INDUSTRY","100467335",false,"NCT05365425","Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia","Effect of Choline Fenofibrate on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined Dyslipidemia","Inclusion Criteria:\n\n* Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit\n* Male or female of 20 years or over\n* Mixed dyslipidemia: triglyceride 200\\~499 mg\u002FdL, HDL-cholesterol male ≤45 mg\u002FdL or female ≤50 mg\u002FdL\n* Identified carotid artery plaque: carotid intima-media thickness (cIMT) ≥ 1.0 mm\n* Creatinine ≤1.8 mg\u002FdL\n\nExclusion Criteria:\n\n* Dyslipidemia which requires other therapy: triglyceride ≥500 mg\u002FdL or LDL-cholesterol ≥190 mg\u002FdL\n* Uncontrolled hypertension\n* Severe renal dysfunction\n* GOT\u002FGPT \\>120\u002F120 or chronic liver disease\n* Pregnant or childbearing woman who does not have enough contraception\n* Changes of medication related to chronic diseases (diabetes, hypertension, dyslipidemia, etc.) within 3 months\n* Other antiplatlet medication such as cilostazol, clopidogrel (except aspirin)","ALL","20 Years",{"count":75,"type":76},56,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","This is a randomized controlled study to assess the effect of choline fenofibrate compared with policosanol in Korean T2DM patients with asymptomatic atherosclerosis.",[82,83,84],"Dyslipidemia","Atherosclerosis","Diabetes Mellitus, Type 2","2026-05-02",{"date":87,"type":88},"2026-05-05","ACTUAL",{"date":90,"type":88},"2023-06-01",{"date":92,"type":76},"2027-12-31",{"name":5,"class":6},1]